Calgary’s Prostate Cancer Centre is a collaborative institution that together with the Southern Alberta Institute of Urology brings together physicians, nurses and researcher who focus on genitourinary function and disorders. This environment is key not only for the multidisciplinary approach to the treatment of patients but also for the cutting edge research that takes place. The research department at the Centre began operation in 1999. Multiple national and international studies have been conducted at the Centre over the past 15 years.
Current Clinical Trials
Below is a list of the studies we are currently recruiting patients. For additional information on these studies please feel free to contact our research team at 403.943.8953.
GURC: Genitourinary Research Consortium, a multicenter study to document the course of advanced prostate cancer in Canada in terms of disease progression, real-world treatment, and patient management
ProPel: A randomized, double-blind, placebo-controlled, multicentre phase III study of Olaparib plus Abiraterone relative to placebo plus Abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer
Magnitude: A randomized study of niraparib with abiraterone acetate and prednisone vs. abiraterone acetate and prednisone for treatment of metastatic castration-resistant prostate cancer (mCRPC) and DNA-Repair Defects ***(NEW)
Clarity Dx Validation Study: Validation of a new blood test to refine the prediction of clinically significant prostate cancer ***(NEW, coming soon July 2019)
Ongoing Clinical Trials
EMBARK: Study of Enzalutamide plus Leuprolide, Enzalutamide Monotherapy, and placebo plus Leuprolide in men with high-risk nonmetastatic prostate cancer progressing after definitive therapy
ARAMIS: Study of ODM-201 in men with high-risk non-metastatic castration-resistant prostate cancer (m0CRPC)
TITAN: Apalutamide plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Subjects with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
SPARTAN: ARN-509 in men with non-metastatic castration-resistant prostate cancer (m0CRPC)
Enzamet: Enzalutamide as 1st line therapy for men with hormone-sensitive metastatic prostate cancer (mHSPC)
APCaRI: Evaluation of potential biomarkers to help the clinical management of prostate cancer
HERO: A study to evaluate the safety and efficacy of Relugolix in men with advanced prostate cancer
Calgary’s Prostate Cancer Centre has teamed up with the Alberta Cancer Research Biorepository (formerly the cbcf Tumor Bank) for the collection of blood, tissue, urine and semen samples from patients with and at risk of developing cancer. The Tumor Bank has been collecting tissue and blood samples for many years from patients with both cancerous and benign lesions. Within Calgary’s Prostate Cancer Centre, the cbcf Tumor Bank focuses on the collection of blood, urine and semen from men currently being followed in our Active Surveillance Program. However, tissue collection is not limited to prostate cancer alone or specifically to the Active Surveillance program.
The samples collected are stored anonymously and provided to researchers around the world for the development of new treatment and diagnostic tools for cancer. If you are interested in donating to the program, please visit their website or contact Dailene Maennchen at 403.943.8888 for more information.
A lot of work must be done before a drug can be released to the public, or even tested on humans. Much of this work is done in laboratories and is referred to as bench or basic research. The application of this bench or basic science to real life treatment of patients is referred to as translational research (the translation of the laboratory results to meaningful medical practice).
We are pleased to have Dr. Tarek Bismar join our group and bring his expertise in genetic research to our centre. Dr. Bismar will be focusing on translational research at the center and is a renowned genitourinary pathologist with a special interest in prostate cancer research. He has completed fellowship training is in genitourinary pathology at Harvard University and Wayne State.
The Alberta Prostate Cancer Research Initiative (APCaRI) brings together a multi-disciplinary team of prostate cancer scientists, physicians, patients, healthcare employees and an international collaborative network together to positively impact the outcomes and quality of life of those living with prostate cancer by accelerating the translation of new research ideas from the laboratory to the clinic.
Prostate Cancer Registry & Biorepository
Clinical registries improve care by arming doctors and teams treating prostate cancer with information about how their outcomes compare with international standards and other locales. The Alberta Prostate Cancer Registry will allow us to monitor the patterns of care and outcomes of men diagnosed with prostate cancer throughout Alberta, and provide a valuable tool to track how our translational research efforts are impacting outcomes over time. The registry will be linked to a biorepository containing patient specimens that will drive translational research and enable personalized approaches to prostate cancer diagnosis and treatment.
APCaRI team members are applying state-of-the-art genomic, proteomic, metabolomic and transcriptomic analyses to the development of new and better tests for prostate cancer. Clinical validation of these tests requires large numbers of high quality patient biosamples linked to accurate and complete clinical outcome data. Despite growing international efforts to improve biobanking, there is limited availability of high-quality biospecimens linked to well-annotated prospectively collected demographic and clinical information.
The APCaRI Prostate Cancer Registry and Biorepository is a province-wide comprehensive resource that incorporates all prostate cancer patients in Alberta. Biobanking samples from Albertan prostate cancer patients collected through the journey of diagnosis and treatment will translate into enormous benefits because it will lead to tests that are directly applicable to Albertans. Translation of these tests to the clinic within 5 years will have a considerable impact on patients and the healthcare system.
Learn more about APCaRI.